DrugPatentWatch Database Preview
Drugs in Development Information for QAW039
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for QAW039?
QAW039 is an investigational drug.
There have been 18 clinical trials for QAW039.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 7th 2018.
The most common disease conditions in clinical trials are Asthma, Eosinophilia, and Hypersensitivity. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are six US patents protecting this investigational drug and sixty-one international patents.
Summary for QAW039
| US Patents | 6 |
| International Patents | 61 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2018-12-07) |
| Vendors | 24 |
Recent Clinical Trials for QAW039
| Title | Sponsor | Phase |
|---|---|---|
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. | Novartis Pharmaceuticals | Phase 2 |
| A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia | Novartis Pharmaceuticals | Phase 2 |
| Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for QAW039
Top disease conditions for QAW039
Top clinical trial sponsors for QAW039
US Patents for QAW039
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| QAW039 | Start Trial | Pyrrolopyridine derivatives and their use as Crth2 antagonists | Novartis AG (Basel, CH) | Start Trial |
| QAW039 | Start Trial | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | Novartis AG (Basel, CH) | Start Trial |
| QAW039 | Start Trial | Organic compounds | Novartis AG (Basel, CH) | Start Trial |
| QAW039 | Start Trial | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | Novartis AG (Basel, CH) | Start Trial |
| QAW039 | Start Trial | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | Novartis AG (Basel, CH) | Start Trial |
| QAW039 | Start Trial | Antibody molecules to PD-L1 and uses thereof | Novartis AG (Basel, CH) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for QAW039
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| QAW039 | Argentina | 049443 | 2024-06-17 | Start Trial |
| QAW039 | Austria | 378338 | 2024-06-17 | Start Trial |
| QAW039 | Australia | 2005254681 | 2024-06-17 | Start Trial |
| QAW039 | Brazil | PI0512060 | 2024-06-17 | Start Trial |
| QAW039 | Canada | 2569125 | 2024-06-17 | Start Trial |
| QAW039 | China | 101035786 | 2024-06-17 | Start Trial |
| QAW039 | Cyprus | 1107851 | 2024-06-17 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
